Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Rimegepant dissolving tablets treat acute migraine in phase 3 trial

Key clinical point: An orally dissolving tablet formulation of rimegepant has significant effects on pain relief and functional ability at 60 minutes post dose.

Major finding: At 2 hours post dose, patients who received rimegepant orally dissolving tablet were more likely than patients who received placebo to achieve pain freedom (21.2% vs. 10.9%) and freedom from the most bothersome symptom (35.1% vs. 26.8%).

Study details: A phase 3, double-blind, randomized, placebo-controlled, multicenter trial with more than 1,300 patients with migraine.

Disclosures: Biohaven Pharmaceuticals, the developer of the drug, sponsored the study. Dr. Lipton has received honoraria and research support from Biohaven and holds stock in the company. Coauthors are employees of Biohaven.

Citation:

REPORTING FROM AAN 2019